Stem cell transplantation in Hodgkin lymphoma. Review uri icon

Overview

abstract

  • Patients with Hodgkin lymphoma (HL) who relapse following effective front-line therapy are offered salvage second-line chemotherapy regimens followed by high-dose therapy and autologous stem cell transplantation (HDT/ASCT). Randomized studies comparing HDT/ASCT with conventional chemotherapy in patients with relapsed refractory HL have shown significant improvement in progression-free survival and freedom from treatment failure but were not powered to show improvements in overall survival. For patients who relapse after salvage HDT/ASCT, novel therapies exist as a bridge to allogeneic SCT. In this article, we review indications and results of autologous and allogeneic SCT in HL.

publication date

  • September 26, 2014

Research

keywords

  • Drug Therapy
  • Hematopoietic Stem Cell Transplantation
  • Hodgkin Disease
  • Salvage Therapy

Identity

Scopus Document Identifier

  • 84912068971

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2014.08.011

PubMed ID

  • 25459181

Additional Document Info

volume

  • 28

issue

  • 6